October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Hospital, health system mergers reach new heights
- Algorithm enhances decision-making on intermediate-stage liver cancer surgery, treatment
- Hispanic Heritage Month reports highlight awareness, action on organ transplant disparities
- Medicare policy on prior authorization falls short on shifting outpatient surgery trends
- DEA registration validation changes challenge healthcare accreditation
- CMS proposes $2 Drug List Model to reduce out-of-pocket costs for Medicare recipients
- Algorithm enables continuous forecasting of intraoperative blood pressure
- Study: Improper arm positioning during blood pressure measurements can lead to hypertension overdiagnosis
- JAMA video highlights OR sustainability
- AAP releases first opioid prescribing guidelines for children
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement